[ad_1]
A healthcare worker wearing a protective mask works in a laboratory during clinical trials for a Covid-19 vaccine at the Research Centers of America in Hollywood, Florida, U.S., on Wednesday, September 9, 2020.
Photographer: Eva Marie Uzcategui / Bloomberg
Photographer: Eva Marie Uzcategui / Bloomberg
MeterPfizer and GermanyThe interim results of the new coronavirus vaccine candidate announced by Biontech have raised expectations that the end of the pandemic (global epidemic) will be near. But experts warn that there are still many hurdles for the vaccine candidate to overcome.
While preliminary results figures look very promising, vaccine experts note that questions remain about the efficacy and capabilities of vaccine candidates, and there are production and supply issues as well. Pfizer’s clinical trials began less than four months ago, and so far little is known about how long this candidate vaccine will last and how many people will benefit from it.
“The big question is still timing,” said Michael Kinch, a vaccine expert at Washington University in St. Louis, “we have to watch if it will work for more people.” “Continued.
The results of this time were published in the press material, not in the article published after being reviewed. Still, investors skyrocketed and share prices skyrocketed around the world. The US S&P 500 stock index closed for the first time in two months and travel and entertainment-related stocks that traded during the pandemic rebounded.
Michael Osterholm, director of the Center for Infectious Disease Research and Policy (CIDRP) at the University of Minnesota, said the announcements from the two companies “did not tell us what was actually accomplished.” “It is too early to decide how to define this interim result,” he said yesterday in a radio interview.
Both companies have a 90% chance of preventing infectionsAlthough it was announced, it is not clear what type of infection was prevented. A detailed announcement of the effect on severely ill people, such as the elderly, is yet to come.
Ugur Sahin, CEO of Biontech, said that nearly half of the clinical trial participants were elderly, and it can be estimated from preliminary results that it was effective for more than 80% of the elderly. Explained. However, he went on to say that further analysis and confirmation were needed.
William Gruber, senior vice president of clinical vaccine research and development at Pfizer, said the interim results have not led to an exacerbation, but he expects it as the trial progresses.
Original title:
Pfizer Vaccine Results Leave Questions About Safety and Longevity （抜 粋）
